… Other impacts include the risk of LT recipients or live donors acquiring SARS-COV-2 infection
during hospitalization and the possibility of transmission from an undiagnosed donor to a …

… Clinical Characterization and Management of COVID-19 infection, who recommended (in
addition to hospitalization and death) including a form of clinical … of patients living in assisted …

… of the treatment of patients with COVID-19 in our clinic. Clinical results of COVID-19 patients
… Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position …

… guidelines from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
on the treatment of COVID-19 … between RCTs and the real-life use of remdesivir. In a …

… Other impacts include the risk of LT recipients or live donors acquiring SARS-COV-2 infection
during hospitalization and the possibility of transmission from an undiagnosed donor to a …

… of medications used against COVID-19 treatment according to the COVID guideline published
by the … ESCMID COVID-19 Living guidelines: drug treatment and clinical management. …

… Living donation should not be performed on either a donor or recipient who has returned from
countries with COVID-19 outbreaks or who … EASL-ESCMID position paper advises against …

… of drug therapy for patients with active COVID-19 disease, … drugs that may prolong the QT
interval due to potentially life-… the treatment of pneumonia associated with COVID-19 were at …

… to discontinue antimicrobial therapy in … therapy in patients with coronavirus disease 2019
(COVID-19). This review provides an up-to-date overview of the use of PCT in different clinical …

… was shown to be safe and effective in treating early COVID-19, but its favourable impact in
… of remdesivir as a treatment for hospitalised patients with COVID-19 by a propensity score …